Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Nasopharyngeal cancer
Stage/Subtype:  recurrent nasopharyngeal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 64 for your search:
Start Over
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D4193C00002, NCI-2015-01842, NCT02369874
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Buparlisib and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, BKM120, IRB12-1972-CR002, NCT01816984
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2104, NCI-2014-02359, 2014-000579-20, NCT02205398
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B9991004, NCI-2015-02263, 2015-002552-27, JAVELIN MEDLEY, NCT02554812
Carboplatin, Docetaxel and Laboratory-Treated T Cells in Treating Patients With Refractory or Relapsed EBV-Positive Nasopharyngeal Cancer
Phase: Phase II
Type: Treatment
Age: 10 and over
Trial IDs: H-25145, NCI-2013-01143, CADEN, NCT00953420
Docetaxel, Cisplatin, and Cetuximab in Treating Patients With Metastatic or Relapsed Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: ENT0033, NCI-2011-03271, 22329, SU-08222011-8290, NCT01437449
Cetuximab and Dasatinib in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer Previously Treated With Cetuximab and Chemoradiation Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 08-034, NCI-2011-03734, CA180264, NCT01488318
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
Stereotactic Radiosurgery and Cetuximab with or without Docetaxel in Treating Patients with Recurrent Head and Neck Cancer Previously Treated with Radiation Therapy
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 11-112, NCI-2014-01954, REN13090047, UPCI 11-112, NCT02057107
Cetuximab, Paclitaxel, and Carboplatin in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC1330, NCI-2015-00334, NCT02124707
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: D4193C00001, NCI-2015-00060, NCT02207530
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4193C00003, NCI-2015-00612, NCT02319044
Nivolumab in Treating Patients with Recurrent and/or Metastatic Nasopharyngeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1471, NCI-2014-02673, 9742, NCT02339558
Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OMS-I130, NCI-2015-00840, NCT02345330
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Start Over